Melanotan I: Scenesse/Afamelanotide, skin-darkening drug for rare sun-pain disorder
A lab-made hormone that tells the skin to make dark pigment without sun exposure, protecting people with a rare condition (erythropoietic protoporphyria, or EPP) from severe light-triggered pain. FDA-approved.
- Class
- Synthetic α-MSH analog; selective MC1R agonist
- Status
- FDA-approved prescription drug (October 2019); EMA-approved (December 2014) — EPP indication only
- Best-supported effect
- Prevention of phototoxicity in adults with erythropoietic protoporphyria; Phase III RCTs demonstrate median ~69 hours of pain-free sun exposure over 180 days (treated) vs. ~41 hours (placebo)
- Main caveat
- Approved indication is narrow (adults with EPP only, via controlled healthcare-provider-administered implant); cosmetic tanning use via self-injected research-chemical material is a distinct, unapproved use case that does not inherit the approved-indication safety record
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Melanotan I — marketed as Scenesse under its approved drug name afamelanotide — is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), developed at the University of Arizona by Victor Hruby's group in the 1980s. It works by activating a receptor on skin pigment cells called MC1R, which triggers the production of the dark, protective form of skin pigment (eumelanin), independently of UV exposure. Afamelanotide is an FDA-approved and EMA-approved prescription medicine — the only one of the "Melanotan" compounds to reach regulatory approval — licensed exclusively for preventing phototoxic pain in adults with erythropoietic protoporphyria (EPP), a rare genetic condition that causes severe sun sensitivity.
The stored sequence SYSMEHFRWGKPV is the native alpha-MSH backbone. The active molecule differs in four ways: the methionine at position 4 is replaced with norleucine (Nle⁴, conferring protease resistance), the phenylalanine at position 7 is replaced with D-phenylalanine (D-Phe⁷, enhancing MC1R affinity and duration of action), the N-terminus is acetylated, and the C-terminus is amidated — giving the full modified sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. Together these modifications make afamelanotide approximately 100–1,000 times more potent than native alpha-MSH, with a markedly extended duration of action (Ericson et al. 2017).
Clinuvel Pharmaceuticals (originally Epitan) licensed the molecule and pivoted from cosmetic-tanning development to an orphan-drug strategy for EPP, winning EMA approval in December 2014 and FDA approval in October 2019. The approved formulation is a 16 mg biodegradable poly(DL-lactide-co-glycolide) (PLGA) subcutaneous implant administered by a certified healthcare provider every 60 days during anticipated sun-exposure periods. The free-peptide plasma half-life is approximately 30 minutes; the PLGA implant provides approximately 60 days of sustained release.
Afamelanotide is pharmacologically distinct from Melanotan II, which is a cyclic heptapeptide with broad, non-selective activity across the melanocortin receptor family. Afamelanotide's preferential activity at MC1R — rather than MC3R, MC4R, or MC5R — underlies both its clinical target (eumelanin synthesis) and its comparatively cleaner acute side-effect profile relative to Melanotan II (Ericson et al. 2017).
History
Alpha-MSH was identified as a pituitary hormone regulating skin pigmentation in the mid-twentieth century. Victor Hruby's group at the University of Arizona undertook systematic structure–activity relationship studies of alpha-MSH analogs during the 1970s and 1980s, establishing that substituting methionine at position 4 with norleucine and phenylalanine at position 7 with its D-isomer produced a dramatically more potent and metabolically stable agonist — [Nle⁴,D-Phe⁷]-alpha-MSH, the compound now known as afamelanotide or NDP-alpha-MSH (Ericson et al. 2017). Hruby's group and colleagues also explored this scaffold for selective melanocortin receptor pharmacology over subsequent decades (Hruby et al. 2011).
Early clinical pharmacology work in the 1990s confirmed dose-dependent skin pigmentation in healthy human subjects. Clinuvel Pharmaceuticals eventually identified EPP — a rare ferrochelatase-deficiency disease in which protoporphyrin IX accumulation causes severe phototoxic pain on even brief light exposure — as the target indication, restructuring development around an orphan-drug pathway. The biodegradable PLGA implant delivery format was designed to provide sustained release appropriate for chronic EPP photoprotection. EMA approval came in December 2014, making Scenesse the first treatment approved for EPP in the EU; FDA approval followed in October 2019.
What it does
In EPP patients, afamelanotide builds a UV-independent eumelanin layer in the skin that acts as a photoprotective barrier, reducing the sensitivity of skin cells to protoporphyrin IX-mediated phototoxic activation by light. This allows EPP patients — who typically live severely photo-restricted lives — to tolerate more sun exposure before experiencing pain. The pivotal Phase III clinical trials (CUV039 and CUV029) demonstrated that treated EPP patients tolerated a median of approximately 69 hours of pain-free sun exposure over 180 days, compared with approximately 41 hours in the placebo group (Langendonk et al., NEJM 2015).
Beyond EPP, the biological effects of MC1R activation by afamelanotide include:
- Eumelanin synthesis: MC1R agonism drives the cAMP-PKA signaling cascade, activating CREB and upregulating MITF — the master transcription factor for melanogenic enzymes including tyrosinase, TRP-1, and TRP-2 — producing UV-independent skin darkening (García-Borrón et al. 2014).
- DNA repair enhancement: MC1R signaling is linked to enhanced nucleotide excision repair (NER) of UV-induced photoproducts, including cyclobutane pyrimidine dimers; available literature reports approximately a 50% reduction in epidermal sunburn cells and significant reduction in thymine dimer formation under MC1R activation.
- Anti-inflammatory modulation: MC1R activation modulates antioxidant and inflammatory pathways in melanocytes (García-Borrón et al. 2014).
The melanocortin pathway and energy homeostasis research has established that MC1R is one of five melanocortin receptor subtypes with distinct physiological roles; MC1R's primary role in melanocyte function and pigmentation is well characterized (Yeo et al. 2021).
Evidence
- Human: FDA- and EMA-approved for EPP based on two pivotal Phase III multicenter RCTs (CUV039, Langendonk et al. NEJM 2015; CUV029) demonstrating significant improvement in pain-free sun-exposure time over 180 days. Post-marketing observational cohort data covering 8+ years in EPP populations across European and US clinical practice extend the safety and effectiveness record. A Phase II RCT in adults with vitiligo, published in JAMA Dermatology, demonstrated a repigmentation signal when afamelanotide was combined with narrowband UVB phototherapy; no Phase III has been completed and no regulatory approval has been obtained for this indication. A Phase IIa proof-of-concept study in acute ischemic stroke has been published; no adequately powered efficacy trial has been completed. Early controlled human pharmacology studies in the 1990s confirmed dose-dependent pigmentation in healthy, non-EPP subjects.
- Animal: The MC1R pharmacology underpinning afamelanotide is among the most thoroughly characterized receptor systems in dermatology; the preclinical development program is described across the melanocortin biology literature as comprehensive (Ericson et al. 2017).
- In vitro: MC1R-mediated cAMP-PKA signaling, CREB phosphorylation, MITF upregulation, melanogenic enzyme induction (tyrosinase, TRP-1, TRP-2), and nucleotide excision repair enhancement are characterized at the molecular level (García-Borrón et al. 2014).
Known effects
- Prevention of phototoxicity in adults with EPP — FDA-approved (2019); EMA-approved (2014); TGA-approved (Australia); Swissmedic-approved (Switzerland)
- UV-independent eumelanin-mediated skin pigmentation — Human; clinical pharmacology label and Phase III data
- Vitiligo repigmentation (combination with narrowband UVB phototherapy) — Phase II RCT; no Phase III; not approved
- Neuroprotection in acute ischemic stroke — Phase IIa proof-of-concept; no adequately powered efficacy trial; not established
- Cosmetic tanning in healthy adults — Controlled human pharmacology data; no long-term cosmetic-cycling safety data; does not inherit approved-indication safety record
Safety signals
The following signals are reported from the approved EPP indication clinical program and post-marketing data:
- Implant site reaction / discoloration — approximately 21%; most common adverse event in Phase III trials and label
- Nausea — approximately 19%; reported as milder than that associated with Melanotan II in available literature
- Oropharyngeal pain — approximately 7% in pivotal trials
- Fatigue — approximately 6% in pivotal trials
- Generalized skin darkening — expected pharmacological consequence of MC1R activation; present in all treated patients; not classified as an adverse event in the EPP context but requires dermatological monitoring
- Nevus darkening / new nevus formation — darkening of existing moles documented in a subset of EPP-treated patients on the approved label; case reports and dermatology observations document new nevus formation and dysplastic changes in cosmetic melanotan users; controlled incidence data in either population are absent
- Long-term melanoma risk — over a decade of post-marketing EPP cohort surveillance has not identified a clear melanoma signal; pharmacological MC1R activation on melanocytes warrants continued monitoring; no cancer-endpoint trial has been conducted
- Effects beyond 8–10 years of continuous treatment — outcomes in EPP patients treated continuously beyond this window are still being collected; no new safety signals identified in published cohorts
The label and source literature note the following as subjects of caution or relative contraindication in the approved EPP indication: pregnancy (not adequately studied; effective contraception generally recommended during treatment); breastfeeding (lactation transfer not characterized); history of melanoma, atypical nevus syndrome, or significant melanocytic lesions (dermatological surveillance required); known hypersensitivity to afamelanotide or PLGA implant excipients; and significant hepatic impairment in EPP patients (EPP itself may produce protoporphyric liver disease requiring individualized assessment).
Drug interaction data are limited; afamelanotide is cleared by proteolysis rather than CYP-mediated metabolism. The published vitiligo trials used afamelanotide combined with narrowband UVB phototherapy; additive pigmentary effects are expected in combinations with melanocyte-active therapies.
Important context: Self-injected research-chemical Melanotan I for cosmetic tanning involves the same active molecule as Scenesse but a different dose form, delivery route, monitoring context, and user population. The 8+-year approved-indication safety record does not transfer to community self-injection in healthy adults; no longitudinal safety dataset for that use pattern exists.
Regulatory status
- US (FDA): Approved prescription drug — Scenesse (afamelanotide 16 mg implant), FDA-approved October 2019 for prevention of phototoxicity in adults with EPP. Restricted distribution through Clinuvel-certified specialty centers only; not available through retail pharmacies; not approved for cosmetic tanning.
- EU (EMA): Approved prescription drug — Scenesse EMA-approved December 2014 for EPP; same restricted indication.
- Australia (TGA): Approved — EPP indication.
- Switzerland (Swissmedic): Approved — EPP indication.
- UK (MHRA): Approved for EPP indication per available literature; MHRA has issued warnings against unapproved cosmetic-tanning peptides; current MHRA status should be verified against the current official source.
- WADA: Afamelanotide is captured under WADA S0 (non-approved substances) for any use outside the specific EPP therapeutic supply chain; EPP patients using Scenesse under the approved indication should hold Therapeutic Use Exemption documentation. Current WADA list position should be verified against the current official list.
- Research-chemical sourcing: Afamelanotide or "Melanotan I" sold online for cosmetic tanning is not the approved Scenesse product; purity, sterility, and pharmacokinetic profile are not standardized; FDA, TGA, MHRA, and other authorities have issued warnings against unapproved cosmetic-tanning peptides.
Mechanism
Afamelanotide ([Nle⁴,D-Phe⁷]-α-MSH) binds and activates MC1R — a Gs protein-coupled receptor on epidermal melanocytes — as its primary pharmacological target. MC1R activation triggers the cAMP-PKA signaling cascade: adenylate cyclase produces cAMP, PKA is activated, and CREB (cAMP response element-binding protein) is phosphorylated. CREB drives transcription of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte differentiation and pigment production. MITF in turn upregulates tyrosinase, TRP-1, and TRP-2 — the key melanogenic enzymes — resulting in increased eumelanin production and UV-independent skin pigmentation (García-Borrón et al. 2014).
MC1R signaling also enhances nucleotide excision repair (NER) of UV-induced DNA photoproducts, including cyclobutane pyrimidine dimers, and modulates antioxidant and anti-inflammatory pathways in melanocytes. In EPP, the clinical benefit derives from the eumelanin layer providing a UV-independent photoprotective barrier that reduces sensitivity to protoporphyrin IX-mediated phototoxicity.
MC1R's pharmacological role is situated within a family of five melanocortin receptors (MC1R–MC5R), each with distinct tissue distribution and physiological roles; MC2R mediates ACTH action on the adrenal gland, while MC3R, MC4R, and MC5R play roles in energy homeostasis, feeding behavior, and exocrine gland function, respectively (Dores 2013; Yeo et al. 2021; Cai et al. 2016). Afamelanotide's selectivity profile favoring MC1R over MC3R, MC4R, and MC5R is the pharmacological basis for its melanogenesis-focused clinical activity and its comparatively narrower acute adverse-effect profile relative to Melanotan II, which is a non-selective melanocortin receptor agonist (Ericson et al. 2017).
Open questions
- Long-term melanoma surveillance: Post-marketing EPP cohort data extending more than a decade have not identified a clear melanoma signal, but pharmacological MC1R activation on melanocytes warrants continued monitoring as treatment durations lengthen. Passive surveillance in a small orphan-disease population is not equivalent to a cancer-endpoint trial.
- Quantified nevus risk: Case reports and dermatology observations establish a clinical concern around new nevus formation and existing nevus change. A quantified, controlled incidence estimate in either the EPP-treated or cosmetic-use population is absent.
- Long-term safety of cosmetic self-injection in healthy adults: No longitudinal safety dataset exists for community self-injection cycling. The EPP approval safety record cannot be extrapolated to this different route, population, and monitoring context.
- Vitiligo Phase III: The Phase II RCT demonstrated a repigmentation signal for afamelanotide combined with narrowband UVB phototherapy. Phase III data and regulatory approval for vitiligo have not been established.
- Acute stroke neuroprotection: Phase IIa proof-of-concept data are published. An adequately powered efficacy trial in acute ischemic stroke is pending; clinical efficacy has not been established.
- Xeroderma pigmentosum and other UV-vulnerable genetic conditions: Mechanistic rationale (MC1R activation enhances nucleotide excision repair) is established; clinical trial data remain preliminary.
- Pediatric EPP: The labeled indication covers adults only. Pediatric-specific trial data and regulatory approval are limited.
- Individualized EPP dosing: The 60-day implant interval is a population-level parameter; whether individualized scheduling based on symptom burden, latitude, or protoporphyrin levels improves outcomes has not been formally studied.
Related peptides
- Alpha-MSH — the endogenous 13-residue parent peptide from which afamelanotide was designed; shares the SYSMEHFRWGKPV backbone but lacks the Nle⁴ and D-Phe⁷ stabilizing substitutions
- Melanotan II — cyclic heptapeptide melanocortin analog; non-selective across MC1R, MC3R, MC4R, and MC5R; used in erectile-dysfunction research and cosmetic tanning; broader receptor activity and more pronounced acute side-effect profile relative to afamelanotide; not approved by any regulatory authority
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does afamelanotide actually bind the adrenal receptor MC2R, or is that annotation simply an error carried over from a misreading of related peptide data?
If this target label is wrong, drug researchers could stop including a phantom receptor in safety and interaction models for afamelanotide, making future studies more accurate. It would also clarify that this drug does not trigger adrenal hormone side effects the way ACTH-derived drugs do.
When afamelanotide cuts sun-induced DNA damage, does it work by turning on DNA-repair genes inside skin cells, rather than simply blocking UV with a pigment layer?
If the drug works by activating repair genes, it could help people whose own DNA-repair machinery is weak, such as those with the rare sun-sensitivity disease xeroderma pigmentosum or transplant patients on immunosuppressants. That would mean a broader group of people at high skin-cancer risk might benefit from the drug.
Does the slow-release afamelanotide implant lower inflammatory signals throughout the body by acting on immune cells, separate from its effect on skin color?
If afamelanotide measurably damps down inflammatory signals in immune cells, patients using it for the rare sun-pain disease EPP might also be getting quiet protection against inflammatory conditions. This could open the door to testing it in autoimmune or chronic inflammatory diseases where current options are limited.
Could afamelanotide reduce skin cancer risk in organ-transplant patients by both darkening the skin as a UV barrier and boosting the skin cells' ability to repair sun damage?
Organ-transplant patients on anti-rejection drugs develop skin cancers at rates 40 to 70 times higher than the general population, and there is no approved drug to prevent this. If afamelanotide's dual action of building pigment and activating DNA repair reduces that risk, it could become a second approved use for a drug whose safety is already well-documented.
If one flexible amino acid in afamelanotide is replaced with a rigid one, would the drug stick more selectively to the intended skin receptor and avoid the appetite and sexual-function receptor?
Afamelanotide's current structure weakly activates a receptor tied to appetite and sexual function, which is an unwanted side effect. If a single substitution narrows its action to just the skin receptor, a cleaner version of the drug could be used at higher doses, potentially expanding its use in cancer-prevention settings where a stronger effect is needed.
Is there a single amino acid in afamelanotide that is rapidly chewed up by enzymes in the body, forcing it to be delivered as a slow-release implant rather than a nasal spray or cream?
If researchers can pinpoint exactly which part of the peptide is destroyed by body enzymes, and if a simple swap can fix it, the drug might eventually be formulated as a nasal spray or topical cream. That would make it far easier to use for the rare sun-pain disease it treats, and could open the door to broader preventive applications.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8078250885009766 | openfold3-mlx |
| ranking score | 0.8784961700439453 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.779 | global PDE — lower = better |
| disorder | 0.170 | fraction disordered |
| chain pair ipTM (A, B) | 0.808 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | aedd8f3eb814e392… |
| hardware | apple_m4_base_16gb |
| mlx version | 0.31.1 |
| python | 3.14.3 |
| random seed | 42 |
| msa strategy | colabfold |
| diffusion samples | 1 |
| runtime | 174s |
| predicted by | mlx@peptide |
| predicted at | 2026-04-22 |
python3 openfold3/run_openfold.py predict --query_json {query.json} --runner_yaml examples/example_runner_yamls/mlx_runner.yml --output_dir {output_dir} --num_diffusion_samples 1 ▸citationbibtex
@peptide{pep10666,
sequence = {SYSMEHFRWGKPV},
target = {mc1r},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}